ACA
TVTX icon

Apis Capital Advisors’s Travere Therapeutics TVTX Stock Holding History

Apis Capital Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.36M Buy
+112,000
New +$4.97M 0.62% 38
2026
Q1 		– Sell
-186,002
Closed -$7.11M – 63
2025
Q4 		$7.11M Buy
186,002
+20,002
+12% +$650K 1.24% 23
2025
Q3 		$3.97M Buy
+166,000
New +$3.12M 0.88% 25

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Apis Capital Advisors's TVTX Position: Q2 2026 in Review

Apis Capital Advisors opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 112,000 shares worth $6.36M. The stake represents 0.62% of the portfolio and ranks #38 among its holdings. This is a return to the name: Apis Capital Advisors previously reported a position in TVTX as recently as Q4 2025.

Apis Capital Advisors first reported a position in TVTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $7.11M in Q4 2025. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Apis Capital Advisors held 112,000 shares of Travere Therapeutics worth $6.36M as of Q2 2026.
  • Travere Therapeutics was a new Apis Capital Advisors position in Q2 2026.
  • Travere Therapeutics made up 0.62% of Apis Capital Advisors's portfolio in Q2 2026, its #38 holding.
  • Apis Capital Advisors first reported a position in Travere Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Apis Capital Advisors's Travere Therapeutics position peaked at $7.11M in Q4 2025.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Apis Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.